Sun Pharma shares slip 3% after BofA downgrade on premium valuations

Shares of Sun Pharmaceutical fell as much as 2.8% on Tuesday to an intraday low of Rs 1,610 on the BSE after Bank of America Securities downgraded the stock to 'underperform' from 'neutral', citing risks to premium valuations and slower-than-expected execution in speciality *****